Stockscreener 앱 받기
7.81
2.98%
-0.24
시장 영업 전:
9.90
2.09
+26.76%
전일 마감가:
$8.05
열려 있는:
$7.775
하루 거래량:
3,288
Relative Volume:
0.20
시가총액:
$37.80M
수익:
$2.61M
순이익/손실:
$1.69M
주가수익비율:
26.01
EPS:
0.3003
순현금흐름:
-
1주 성능:
-1.25%
1개월 성능:
+0.13%
6개월 성능:
-12.25%
1년 성능:
-7.90%
1일 변동 폭
$7.53
$7.81
1주일 범위
$7.53
$8.11
52주 변동 폭
$7.19
$10.00
Daxor Corporation Stock (DXR) Company Profile
명칭
Daxor Corporation
전화
212-330-8500
주소
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
DXR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
7.81 | 37.80M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
588.50 | 209.89B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
227.21 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
91.65 | 45.33B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
237.18 | 34.84B | 4.93B | 1.25B | 1.38B | 8.47 |
|
WST
West Pharmaceutical Services Inc
|
330.47 | 23.97B | 2.88B | 499.60M | 321.60M | 6.74 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-05-16 | 개시 | Ascendiant Capital Markets | Buy |
Daxor Corporation 주식(DXR)의 최신 뉴스
Where are the Opportunities in (DXR) - Stock Traders Daily
Reviewing Becton, Dickinson and Company (NYSE:BDX) and Daxor (NASDAQ:DXR) - Defense World
(DXR) Technical Pivots with Risk Controls - Stock Traders Daily
Head to Head Contrast: Daxor (NASDAQ:DXR) versus Titan Medical (NASDAQ:TMDIF) - Defense World
(DXR) Long Term Investment Analysis - Stock Traders Daily
Nemaura Medical (NASDAQ:NMRD) versus Daxor (NASDAQ:DXR) Head to Head Comparison - Defense World
Daxor (NYSEAMERICAN:DXR) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell? - Defense World
Daxor (NASDAQ:DXR) Shares Up 0.8% – Should You Buy? - Defense World
When (DXR) Moves Investors should Listen - Stock Traders Daily
Reviewing Embecta (NASDAQ:EMBC) and Daxor (NASDAQ:DXR) - Defense World
Daxor (NYSEAMERICAN:DXR) Stock Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum - GlobeNewswire
Daxor Expands Blood Analysis Service to Major Health Networks, Reports Record-Breaking Quarter - StockTitan
Daxor Expands Its BVA-100?? Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum - Marketscreener.com
Daxor corp CEO Michael Feldschuh acquires 45,000 shares By Investing.com - Investing.com Nigeria
Daxor corp CFO Michel acquires 4,750 shares at no cost By Investing.com - Investing.com Nigeria
Daxor's chief scientific officer acquires 32,000 shares By Investing.com - Investing.com Canada
Daxor's chief scientific officer acquires 32,000 shares - Investing.com
Daxor corp CFO Michel acquires 4,750 shares at no cost - Investing.com
Daxor corp CEO Michael Feldschuh acquires 45,000 shares - Investing.com
How the (DXR) price action is used to our Advantage - Stock Traders Daily
Daxor (NYSEAMERICAN:DXR) Stock Price Down 2.1% – Time to Sell? - Defense World
Daxor (NASDAQ:DXR) & Co-Diagnostics (NASDAQ:CODX) Critical Survey - Defense World
(DXR) On The My Stocks Page - Stock Traders Daily
DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24 - The Manila Times
DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC - GlobeNewswire
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Long Term Trading Analysis for (DXR) - Stock Traders Daily
Short Interest in Daxor Co. (NASDAQ:DXR) Rises By 39.6% - Defense World
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device - The Manila Times
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024 - GlobeNewswire
Daxor (NYSEAMERICAN:DXR) Stock Passes Above Two Hundred Day Moving Average of $0.00 - Defense World
(DXR) Technical Data - Stock Traders Daily
Daxor announces review published in journal on BVA - TipRanks
Newly Published Review Highlights the Pivotal Role of - GlobeNewswire
Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management - StockTitan
Daxor (NASDAQ:DXR) Price Target Raised to $24.75 at Ascendiant Capital Markets - Defense World
Daxor secures $300K from LaunchTN for blood analyzer tech - Investing.com India
Daxor receives $300K matching fund award from Launch Tennessee - TipRanks
Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee - GlobeNewswire
DXRDaxor Corporation Latest Stock News & Market Updates - StockTitan
Central Florida hospital implements Daxor BVA-100 blood volume diagnostic - TipRanks
Leading Central Florida Hospital Implements Daxor’s - GlobeNewswire
Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care - StockTitan
Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder Letter - GlobeNewswire
Daxor reports doubled revenue, secures government contracts - Investing.com
Daxor Corporation (DXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.10%
0.93%
자본화:
|
볼륨(24시간):